Analysts Set Expectations for Perspective Therapeutics Q1 Earnings

Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) – Equities research analysts at Brookline Capital Markets issued their Q1 2027 earnings per share estimates for shares of Perspective Therapeutics in a report released on Tuesday, August 11th. Brookline Capital Markets analyst K. Dolliver anticipates that the company will earn ($0.26) per share for the quarter. The consensus estimate for Perspective Therapeutics’ current full-year earnings is ($1.10) per share. Brookline Capital Markets also issued estimates for Perspective Therapeutics’ Q2 2027 earnings at ($0.27) EPS, Q3 2027 earnings at ($0.30) EPS and FY2027 earnings at ($1.14) EPS.

Perspective Therapeutics (NYSEAMERICAN:CATX) last issued its earnings results on Monday, August 10th. The company reported ($0.22) earnings per share for the quarter, topping the consensus estimate of ($0.25) by $0.03. The firm had revenue of $0.08 million for the quarter, compared to analyst estimates of $0.09 million. Perspective Therapeutics had a negative return on equity of 44.22% and a negative net margin of 28,467.97%.

Several other analysts also recently weighed in on the stock. Wedbush reiterated an “outperform” rating and issued a $11.00 price objective on shares of Perspective Therapeutics in a research report on Tuesday, May 5th. BTIG Research restated a “buy” rating on shares of Perspective Therapeutics in a research report on Friday, July 24th. Finally, Piper Sandler dropped their price target on shares of Perspective Therapeutics from $16.00 to $14.00 and set an “overweight” rating on the stock in a research note on Tuesday. Eight analysts have rated the stock with a Buy rating, According to MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $12.38.

Perspective Therapeutics Stock Performance

Perspective Therapeutics stock opened at $3.26 on Thursday. The company has a 50-day simple moving average of $3.08 and a 200-day simple moving average of $3.94. Perspective Therapeutics has a one year low of $1.96 and a one year high of $6.16.

Institutional Trading of Perspective Therapeutics

Institutional investors have recently made changes to their positions in the stock. Aigen Investment Management LP acquired a new position in shares of Perspective Therapeutics during the fourth quarter valued at approximately $28,000. Russell Investments Group Ltd. lifted its position in Perspective Therapeutics by 184.1% in the third quarter. Russell Investments Group Ltd. now owns 8,449 shares of the company’s stock worth $29,000 after purchasing an additional 5,475 shares during the period. nVerses Capital LLC acquired a new stake in Perspective Therapeutics in the fourth quarter worth approximately $31,000. AXQ Capital LP boosted its stake in Perspective Therapeutics by 24.2% during the 4th quarter. AXQ Capital LP now owns 12,749 shares of the company’s stock valued at $35,000 after purchasing an additional 2,481 shares in the last quarter. Finally, Engineers Gate Manager LP bought a new position in Perspective Therapeutics during the 4th quarter valued at $35,000. 54.66% of the stock is owned by institutional investors and hedge funds.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.